Application of New Data in B-Cell Malignancies From ASCO and EHA 2020: CLL
Listen to Jennifer R. Brown, MD, PhD, and John Allan, MD, discuss the implications of recent trial results in CLL presented at the 2020 annual meetings of the American Society of Clinical Oncology (ASCO) and the European Hematology Association (EHA).
Decera Clinical Education Oncology Podcast
Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this episode, Jennifer R. Brown, MD, PhD, and John Allan, MD, discuss recent key clinical trial results in CLL presented at the 2020 annual meetings of the American Society of Clinical Oncology (ASCO) and the European Hematology Association (EHA). Studies and topics include:
- ASCEND: acalabrutinib vs idelalisib plus rituximab or BR
- ACE-CL-001: acalabrutinib long-term efficacy
- CLL14: Venetoclax plus obinutuzumab
- CLARITY: Ibrutinib plus venetoclax
- Measurable residual disease (MRD)
- Complex karyotypes
- Zanubrutinib plus obinutuzumab and venetoclax
Presenters:
Jennifer R. Brown, MD, PhD
Associate Professor of Medicine
Department of Hematologic Malignancies
Dana-Farber Cancer Institute
Harvard Medical School
Director, CLL Center
Department of Medical Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts
John Allan, MD
Assistant Professor of Medicine
Division of Hematology and Medical Oncology
Weill Cornell Medicine
New York, New York
Content based on an online CME program supported by an educational grant from AstraZeneca.
Link to full program: https://bit.ly/3aSfekM
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.